Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

Vorasidenib 40 mg. objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary

Vorasidenib Phase 1 doses. objective response rate: 18%, Phase 1

Safusidenib (AB-218, DS-1001) 250 mg. confirmed objective response rate: 51.9%, median follow-up 38.8 months

Olutasidenib 150 mg. objective response rate: 8%, 2 of 25

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.